Sorin is now LivaNova. Learn more here

Oct 05, 2015

SORIN GROUP STARTS FIRST RANDOMIZED, CONTROLLED TRIAL COMPARING THE PERCEVAL SUTURELESS VALVE TO STANDARD BIOPROSTHESES

PERSIST-AVR trial will recruit patients with severe aortic valve disease at 60 sites worldwide

MILAN, October 5 2015 – Sorin Group, a global medical device company and a leader in the treatment of cardiovascular diseases, today announced the initiation of PERSIST-AVR (Perceval Sutureless Implant Vs Standard Aortic Valve Replacement), the first international, prospective, post-market randomized multi-center trial evaluating the Perceval sutureless aortic valve compared to standard sutured bioprostheses in patients with aortic valve disease.

Engineered to restore and preserve natural valve performance, Perceval is a sutureless heart valve for patients who require an aortic valve replacement. As a new generation of aortic bioprostheses, the sutureless Perceval valve offers potential patient advantages including reduced ICU stay, ventilation time, and need for blood transfusion compared to traditional sutured valves.

To view full text release.

Latest News

Version unknown | Revision 99192 | Status unstable | SessionId F8043ED951397A4330FD5ED37BDCF06B.jvm1